fluoxetine has been researched along with Drug-Related Side Effects and Adverse Reactions in 25 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors set up two groups, the treatment group and the control group, to observe the influence of electro-acupuncture on the side effects produced by fluoxetine in the treatment of depression." | 9.14 | Influence of electro-acupuncture on the side effects of fluoxetine on depression patients. ( Liu, LY; Lu, Q; Wang, LL, 2009) |
| "The authors set up two groups, the treatment group and the control group, to observe the influence of electro-acupuncture on the side effects produced by fluoxetine in the treatment of depression." | 5.14 | Influence of electro-acupuncture on the side effects of fluoxetine on depression patients. ( Liu, LY; Lu, Q; Wang, LL, 2009) |
| "Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo." | 2.74 | Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. ( Curry, JF; Emslie, GJ; Hughes, JL; Kennard, BD; Kratochvil, CJ; March, JS; Mayes, TL; Reinecke, MA; Rohde, P; Silva, SG; Vitiello, B, 2009) |
| "Predictions of drug-drug interactions (DDIs) are commonly performed for single inhibitors, but interactions involving multiple inhibitors also frequently occur." | 2.48 | In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors. ( Isoherranen, N; Lutz, JD, 2012) |
| " From a knowledge of pharmacokinetics, it can be shown that stopping a drug for just 1 half-life and then resuming it at half the dose results in the immediate achievement of steady state; that is, there is no need to wait for 4 additional half-lives as with the usual strategy of dose reduction without dosing interruption." | 1.72 | Practical Psychopharmacology: Using a Knowledge of Pharmacokinetics to More Rapidly Stabilize Patients at Lower Drug Doses. ( Andrade, C, 2022) |
| "Investigating adverse events associated with antidepressant treatments in adolescents is important given the concerns about increased risk of suicidal ideation and behavior in this age group." | 1.51 | Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine. ( Dudley, AL; Finnin, L; Gordon, MS; Klimkeit, EI; Melvin, GA; Taffe, J; Tonge, B, 2019) |
| "Melatonin has been shown to palliate different lesions by scavenging free radicals, but its role in the reduction of the fluoxetine-induced injuries has been little known." | 1.46 | Protective effects of melatonin on long-term administration of fluoxetine in rats. ( Khaksar, M; Oryan, A; Rahbarghazi, R; Rezabakhsh, A; Sayyari, M, 2017) |
| " There were no published papers on adverse drug reactions (ADRs) of fluoxetine analyzing spontaneous adverse events reports." | 1.46 | Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. ( Choi, HJ; Kim, MS; Kim, S; Park, BJ; Park, K; Yang, BR, 2017) |
| "Much recent research aims to identify evidence for Drug-Drug Interactions (DDI) and Adverse Drug reactions (ADR) from the biomedical scientific literature." | 1.43 | MONITORING POTENTIAL DRUG INTERACTIONS AND REACTIONS VIA NETWORK ANALYSIS OF INSTAGRAM USER TIMELINES. ( Correia, RB; Li, L; Rocha, LM, 2016) |
| "Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids." | 1.38 | In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Fischer, H | 1 |
| Atzpodien, EA | 1 |
| Csato, M | 1 |
| Doessegger, L | 1 |
| Lenz, B | 1 |
| Schmitt, G | 1 |
| Singer, T | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Andrade, C | 3 |
| Yildiz, A | 1 |
| Siafis, S | 1 |
| Mavridis, D | 1 |
| Vieta, E | 1 |
| Leucht, S | 1 |
| Campbell, S | 1 |
| Otten, H | 1 |
| Anand, V | 1 |
| Magalhães, P | 1 |
| Alves, G | 1 |
| Fortuna, A | 1 |
| Llerena, A | 1 |
| Falcão, A | 1 |
| Khaksar, M | 1 |
| Oryan, A | 1 |
| Sayyari, M | 1 |
| Rezabakhsh, A | 1 |
| Rahbarghazi, R | 1 |
| Kim, S | 1 |
| Park, K | 1 |
| Kim, MS | 1 |
| Yang, BR | 1 |
| Choi, HJ | 1 |
| Park, BJ | 1 |
| Melvin, GA | 1 |
| Finnin, L | 1 |
| Taffe, J | 1 |
| Dudley, AL | 1 |
| Klimkeit, EI | 1 |
| Gordon, MS | 1 |
| Tonge, B | 1 |
| Correia, RB | 1 |
| Li, L | 1 |
| Rocha, LM | 1 |
| Kennard, BD | 1 |
| Silva, SG | 1 |
| Mayes, TL | 1 |
| Rohde, P | 1 |
| Hughes, JL | 1 |
| Vitiello, B | 1 |
| Kratochvil, CJ | 1 |
| Curry, JF | 1 |
| Emslie, GJ | 1 |
| Reinecke, MA | 1 |
| March, JS | 1 |
| Liu, LY | 1 |
| Lu, Q | 1 |
| Wang, LL | 1 |
| Bobo, WV | 1 |
| Shelton, RC | 1 |
| Lutz, JD | 1 |
| Isoherranen, N | 1 |
| Richards, SM | 1 |
| Kelly, SE | 1 |
| Hanson, ML | 1 |
| Preskorn, SH | 1 |
| Ciummo, PE | 1 |
| Katz, NL | 1 |
| Goldstein, DJ | 1 |
| Wilson, MG | 1 |
| Cherin, P | 1 |
| Colvez, A | 1 |
| Deville de Periere, G | 1 |
| Sereni, D | 1 |
| Stipp, D | 1 |
| Lyszkiewicz, DA | 1 |
| Gerichhausen, S | 1 |
| Björnsdóttir, I | 1 |
| Einarson, TR | 1 |
| Koren, G | 1 |
| Einarson, A | 1 |
4 reviews available for fluoxetine and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Topics: Adult; Bipolar Disorder; Depression; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxe | 2023 |
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.
Topics: Adult; Age Factors; Antidepressive Agents; Benzodiazepines; Depression; Drug Combinations; Drug Inte | 2010 |
In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.
Topics: Algorithms; Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Are | 2012 |
Adverse event frequencies generate hypotheses of efficacy and safety.
Topics: Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Humans; Obesity; Placebos; Randomized C | 1993 |
2 trials available for fluoxetine and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj | 2009 |
Influence of electro-acupuncture on the side effects of fluoxetine on depression patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Drug-Related Side Effects and Adv | 2009 |
19 other studies available for fluoxetine and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Practical Psychopharmacology: Using a Knowledge of Pharmacokinetics to More Rapidly Stabilize Patients at Lower Drug Doses.
Topics: Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Half-Life; Humans; Psychopharmacology; | 2022 |
Practical Psychopharmacology: Using a Knowledge of Pharmacokinetics to More Rapidly Stabilize Patients at Lower Drug Doses.
Topics: Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Half-Life; Humans; Psychopharmacology; | 2022 |
Practical Psychopharmacology: Using a Knowledge of Pharmacokinetics to More Rapidly Stabilize Patients at Lower Drug Doses.
Topics: Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Half-Life; Humans; Psychopharmacology; | 2022 |
Practical Psychopharmacology: Using a Knowledge of Pharmacokinetics to More Rapidly Stabilize Patients at Lower Drug Doses.
Topics: Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Half-Life; Humans; Psychopharmacology; | 2022 |
CYP450 Genetic Polymorphisms: Generalized Tonic-Clonic Seizure after Intentional Fluoxetine and Melatonin Overdose.
Topics: Cytochrome P-450 Enzyme System; Drug Overdose; Drug-Related Side Effects and Adverse Reactions; Fluo | 2023 |
Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: A PK/PD analysis of the influence of (non-)genetic factors.
Topics: Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Drug Monitoring; Drug-Re | 2020 |
Protective effects of melatonin on long-term administration of fluoxetine in rats.
Topics: Animals; Antioxidants; Body Weight; Drug-Related Side Effects and Adverse Reactions; Erythrocyte Cou | 2017 |
Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database.
Topics: Adverse Drug Reaction Reporting Systems; China; Data Mining; Databases, Factual; Drug Labeling; Drug | 2017 |
Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.
Topics: Absenteeism; Adolescent; Adolescent Behavior; Anxiety Disorders; Cognitive Behavioral Therapy; Combi | 2019 |
MONITORING POTENTIAL DRUG INTERACTIONS AND REACTIONS VIA NETWORK ANALYSIS OF INSTAGRAM USER TIMELINES.
Topics: Antidepressive Agents, Second-Generation; Computational Biology; Drug Interactions; Drug Monitoring; | 2016 |
Zooplankton chitobiase activity as an endpoint of pharmaceutical effect.
Topics: Acetylglucosaminidase; Animals; Atorvastatin; Biological Assay; Daphnia; Dose-Response Relationship, | 2008 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; | 2008 |
Interactions and drug-metabolizing enzymes.
Topics: Adolescent; Adult; Anti-Allergic Agents; Antidepressive Agents, Second-Generation; Antifungal Agents | 1995 |
Risk of syncope in the elderly and consumption of drugs: a case-control study.
Topics: Acepromazine; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antiparkinson Agent | 1997 |
A DNA tragedy.
Topics: Adverse Drug Reaction Reporting Systems; Biotransformation; Child; Cytochrome P-450 CYP2D6; Drug-Rel | 2000 |
Evidence based information on drug use during pregnancy: a survey of community pharmacists in three countries.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antitrichomonal Agents; Canada; Ca | 2001 |